Suriyawut Suriya/iStock via Getty Images
- Taking Novo Nordisk’s older GLP-1 medication Saxenda (liraglutide) while regularly exercising led to maintaining bone mineral density (BMD) while losing weight, according to a new study.
- Researchers conducted a secondary analysis of a randomized clinical trial of 195 obese adults. Results showed that exercise and Saxenda preserved hip, spine, and forearm BMD while Saxenda, which is approved for weight loss, alone reduced hip and spine BMD compared with placebo or exercise alone.
- They also noted that while Saxenda and exercise alone led to similar weight loss, Saxenda treatment only was associated with reduced BMD.
- The results were published in JAMA Network Open.
- Novo’s Wegovy (semaglutide), also a GLP-1, is also approved for weight loss, as is Eli Lilly’s (LLY) Zepbound (tirzepatide), which is considered a dual GIP/GLP-1 receptor co-agonist.
